266 related articles for article (PubMed ID: 21812871)
1. Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: a high-resolution PET study.
Leroy C; Karila L; Martinot JL; Lukasiewicz M; Duchesnay E; Comtat C; Dollé F; Benyamina A; Artiges E; Ribeiro MJ; Reynaud M; Trichard C
Addict Biol; 2012 Nov; 17(6):981-90. PubMed ID: 21812871
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease.
Fazio P; Svenningsson P; Forsberg A; Jönsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A
J Nucl Med; 2015 May; 56(5):714-20. PubMed ID: 25791993
[TBL] [Abstract][Full Text] [Related]
3. Age-related decline in dopamine transporter in human brain using PET with a new radioligand [¹⁸F]FE-PE2I.
Shingai Y; Tateno A; Arakawa R; Sakayori T; Kim W; Suzuki H; Okubo Y
Ann Nucl Med; 2014 Apr; 28(3):220-6. PubMed ID: 24385293
[TBL] [Abstract][Full Text] [Related]
4. Assessment of 11C-PE2I binding to the neuronal dopamine transporter in humans with the high-spatial-resolution PET scanner HRRT.
Leroy C; Comtat C; Trébossen R; Syrota A; Martinot JL; Ribeiro MJ
J Nucl Med; 2007 Apr; 48(4):538-46. PubMed ID: 17401089
[TBL] [Abstract][Full Text] [Related]
5. Striatal and Extrastriatal Dopamine Transporter Availability in Schizophrenia and Its Clinical Correlates: A Voxel-Based and High-Resolution PET Study.
Artiges E; Leroy C; Dubol M; Prat M; Pepin A; Mabondo A; de Beaurepaire R; Beaufils B; Korwin JP; Galinowski A; D'Albis MA; Santiago-Ribeiro MJ; Granger B; Tzavara ET; Martinot JL; Trichard C
Schizophr Bull; 2017 Sep; 43(5):1134-1142. PubMed ID: 28177089
[TBL] [Abstract][Full Text] [Related]
6. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients.
Sonni I; Fazio P; Schain M; Halldin C; Svenningsson P; Farde L; Varrone A
J Nucl Med; 2016 Oct; 57(10):1529-1534. PubMed ID: 27230923
[TBL] [Abstract][Full Text] [Related]
7. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Tanaka K
Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377
[TBL] [Abstract][Full Text] [Related]
8. Lower midbrain dopamine transporter availability in depressed patients: Report from high-resolution PET imaging.
Dubol M; Trichard C; Leroy C; Granger B; Tzavara ET; Martinot JL; Artiges E
J Affect Disord; 2020 Feb; 262():273-277. PubMed ID: 31732277
[TBL] [Abstract][Full Text] [Related]
9. Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility.
Hirvonen J; Johansson J; Teräs M; Oikonen V; Lumme V; Virsu P; Roivainen A; Någren K; Halldin C; Farde L; Hietala J
J Cereb Blood Flow Metab; 2008 May; 28(5):1059-69. PubMed ID: 18183028
[TBL] [Abstract][Full Text] [Related]
10. [11C]LBT-999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET.
Saba W; Valette H; Schöllhorn-Peyronneau MA; Coulon C; Ottaviani M; Chalon S; Dolle F; Emond P; Halldin C; Helfenbein J; Madelmont JC; Deloye JB; Guilloteau D; Bottlaender M
Synapse; 2007 Jan; 61(1):17-23. PubMed ID: 17068778
[TBL] [Abstract][Full Text] [Related]
11. Age-related loss of olfactory sensitivity: association to dopamine transporter binding in putamen.
Larsson M; Farde L; Hummel T; Witt M; Lindroth NE; Bäckman L
Neuroscience; 2009 Jun; 161(2):422-6. PubMed ID: 19348872
[TBL] [Abstract][Full Text] [Related]
12. Dopamine release in chronic cannabis users: a [11c]raclopride positron emission tomography study.
Urban NB; Slifstein M; Thompson JL; Xu X; Girgis RR; Raheja S; Haney M; Abi-Dargham A
Biol Psychiatry; 2012 Apr; 71(8):677-83. PubMed ID: 22290115
[TBL] [Abstract][Full Text] [Related]
13. Low dopamine transporter binding in the nucleus accumbens in geriatric patients with severe depression.
Moriya H; Tiger M; Tateno A; Sakayori T; Masuoka T; Kim W; Arakawa R; Okubo Y
Psychiatry Clin Neurosci; 2020 Aug; 74(8):424-430. PubMed ID: 32363761
[TBL] [Abstract][Full Text] [Related]
14. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
[TBL] [Abstract][Full Text] [Related]
15. [18F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users.
Ceccarini J; Kuepper R; Kemels D; van Os J; Henquet C; Van Laere K
Addict Biol; 2015 Mar; 20(2):357-67. PubMed ID: 24373053
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study.
Jucaite A; Odano I; Olsson H; Pauli S; Halldin C; Farde L
Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):657-68. PubMed ID: 16514530
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of dopamine transporters in human brain using [11C]PE2I and positron emission tomography: evaluation of reference tissue models.
Seki C; Ito H; Ichimiya T; Arakawa R; Ikoma Y; Shidahara M; Maeda J; Takano A; Takahashi H; Kimura Y; Suzuki K; Kanno I; Suhara T
Ann Nucl Med; 2010 May; 24(4):249-60. PubMed ID: 20364374
[TBL] [Abstract][Full Text] [Related]
18. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I.
Sasaki T; Ito H; Kimura Y; Arakawa R; Takano H; Seki C; Kodaka F; Fujie S; Takahata K; Nogami T; Suzuki M; Fujiwara H; Takahashi H; Nakao R; Fukumura T; Varrone A; Halldin C; Nishikawa T; Suhara T
J Nucl Med; 2012 Jul; 53(7):1065-73. PubMed ID: 22689927
[TBL] [Abstract][Full Text] [Related]
19. Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.
Poyot T; Condé F; Grégoire MC; Frouin V; Coulon C; Fuseau C; Hinnen F; Dollé F; Hantraye P; Bottlaender M
J Cereb Blood Flow Metab; 2001 Jul; 21(7):782-92. PubMed ID: 11435790
[TBL] [Abstract][Full Text] [Related]
20. Recovery of dopamine transporters with methamphetamine detoxification is not linked to changes in dopamine release.
Volkow ND; Wang GJ; Smith L; Fowler JS; Telang F; Logan J; Tomasi D
Neuroimage; 2015 Nov; 121():20-8. PubMed ID: 26208874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
